New drug cocktails aim to beat river blindness
NCT ID NCT06070116
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests four different drug combinations in 300 adults with onchocerciasis (river blindness), a parasitic disease. Participants first receive ivermectin to clear skin and eye parasites, then get one of the new combos. The goal is to see which combo is safest and most effective at killing adult worms and preventing disease spread.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ivermectin, Albendazole, Diethylcarbamazine, Moxidectin
- What this could lead to
- If successful, these drug combinations could offer safer and more effective treatments for river blindness, potentially reducing the need for repeated doses.
- What could go wrong
- This is a phase 2 trial with 300 participants, so results are still early. The new combinations may cause side effects or not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCHOCERCA INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bong County Hospital
Bong Town, Bong County, Liberia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI app aims to help frontline workers diagnose neglected skin diseases
- New drug moxidectin put to the test against river blindness in massive safety trial
- Twice-Yearly drug could beat river blindness
- New study aims to bring mental health support to people with neglected skin diseases in ghana
- Massive drug showdown: can a new pill beat river blindness for good?
- River blindness drug trial aims to find right dose for kids